Michael Berman

BeneChill, Inc. develops non-invasive cooling technology for cerebral ischemia treatment. The company was founded by Michael L. Berman and Denise Barbut in 2004 is headquartered in San Diego, CA.

Apnex Medical, Inc. manufactured medical devices. It developed a proprietary active implantable medical device for the treatment of obstructive sleep apnea (OSA). The company was founded by Chad J. Kugler, Michael L. Berman and Robert E. Atkinson in 2006 and was headquartered in St. Paul, MN.

ConcepTx Medical developed and manufactures medical devices. The company was founded in November 2007 and was headquartered in Plymouth, MN.

InspireMD Ltd. is a medical device company, which engages in the development and commercialization of platform technology for the treatment of vascular and coronary disease. It offers MicroNet stent, a device designed to trap and seal thrombus and plaque against the vessel wall, preventing embolization. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

InterValve, Inc. operates as a medical device company which develops aortic valvuloplasty balloons for treatment of calcific aortic stenosis. Its V8 product is enhanced with leaflet hyperextension without increasing the risk of annulus over-distension. The firm also develops tools for the percutaneous and trans-apical aortic valve replacement procedure. The company was founded by Wes Pedersen, Mark Ungs, Robert S. Schwartz and Robert A. Van Tassel in 2008 and is headquartered in Plymouth, MN.

Rebiotix, Inc. develops and commercializes medical therapies. It offers human microbiome, clostridium difficile, inflammatory bowel disease or ulcerative colitis, hepatic encephalopathy, multi-drug resistant organism, and microbiota restoration therapies. The company was founded by Lee A. Jones, Michael Berman, and Erwin A. Kelen in 2011 and is headquartered in Roseville, MN.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Israel Seed Partners is an independent venture capital firm founded in 1995 by Neil Cohen. The firm is headquartered in Jerusalem, Israel.

Transoma Medical, Inc., headquartered in St. Paul, Minnesota, is a medical technology company engaged in developing, manufacturing and distributing implantable, wireless diagnostic and monitoring systems. Transoma is focused specifically on diagnostic and monitoring technology and dedicated to providing physicians with information needed to accurately and quickly diagnose unexplained, infrequent symptoms and to monitor changing, often asymptomatic complex arrhythmias. Transoma has an extensive technology platform based on more than 20 years experience in developing implantable wireless diagnostic systems for use in biomedical research. These innovative tools have played a key role in drug discovery, pre-clinical evaluation of safety and efficacy, and other academic and government basic research. Customers have turned to DSI for more accurate, timely physiological data, highly humane research practices, and faster times to market. In 2003 the Patient Management division was formed utilizing this proven technology platform and paving the way for the formation of Transoma Medical.

Bridgepoint Medical, Inc. develops interventional technology in the field of cardiology. It focuses on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions. The company was founded by Michael L. Berman, Chad J Kugler and Robert E Atkinson in 2005 and is headquartered in Plymouth, MN.

Mazor Robotics Ltd. engages in the development and marketing of robotic guidance system for spinal surgery. Its product is Mazor X. The company was founded by Moshe Shoham and Eliyahu Zehavi in 2001 and is headquartered in Caesarea, Israel.

Lutonix, Inc. develops and commercializes drug coated balloon catheters. Its catheters help to deliver therapeutic dose of paclitaxel. The firm’s catheters are used to treat peripheral and coronary lesions. The company was founded in July 2007 by Dennis Wahr and Lixiao Wang and is headquartered in New Hope, MN.

Angioslide Ltd. operates as a privately-held medical device company. It offers PROTEUS, an angioplasty device that combines the dual functionality of balloon angioplasty and embolic capture and removal features. The company was founded by Eran Hirszowicz, Amos Nahir and Yoav Turgeman in 2005 and is headquartered in Natanya, Israel.

UltraShape redefines aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for fat cell destruction and body sculpting. The company develops and markets clinically proven safe and effective solutions that enhance the lives of patients. The UltraShape proprietary technology employs pulsed (non-thermal) focused ultrasound that instantly, selectively and permanently destroys fat cells without affecting surrounding structures. Founded in 2000, UltraShape has sold Contour I devices in more than 50 countries, demonstrating safety and efficacy. The UltraShape Contour I system, is authorized for marketing outside the U.S. It is the first clinically proven non-invasive solution that offers measurable lasting body sculpting results for men and women with no need for maintenance treatments. The UltraShape system has been shown to be safe and effective in a multi-center controlled trial and numerous other peer-reviewed published independent clinical studies. The device is designed to produce mechanical, non-thermal, acoustic effects which target and selectively destroy (breakdown) fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The latest Contour I V3 system uses Vertical Dynamic Focus™ (VDF) pulsed (non-thermal) focused ultrasound that instantly and permanently destroys fat cells providing patients a convenient noninvasive no-downtime solution to reduce localized fat deposits and body circumference. The UltraShape procedure is based on a natural fat clearance process where triglycerides and cell debris from the destroyed fat cells are processed by the body's natural physiological and metabolic pathways. These pathways are the same that handle fat during weight loss. Results from UltraShape's peer-reviewed published multi-center controlled clinical trial and other independent clinical studies show that the released triglycerides do not accumulate to a clinically significant extent in the blood or liver. Over 200,000 patient treatments have been performed worldwide with the Contour I showing high patient satisfaction while demonstrating safety and efficacy. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guides the operator through a pres-determined treatment algorithm designed to minimize risk of contour irregularities, a common side effect of invasive and non-invasive procedures. The UltraShape procedure is performed during a convenient, 'walk-in, walk-out' session carried out in an office-based environment; it requires no anesthesia or sedation. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The Contour I system is not available for sale in the U.S; the Contour Plus system is an investigational product limited by U.S. law to investigational use only.

ClearCut Medical Ltd. develops proprietary technology and tools for removal of cancer. Its product ClearSightTM MRI System, focuses on breast cancer lumpectomy for intraoperative margin assessment of surgically removed lumps. The firms applications include breast cancer biopsies, margin assessment of skin cancer, prostate cancer, colorectal cancer and lung cancer tissue microstructure. The company was founded by Eyal Kolka and Erez Golan in 2010 and is headquartered in Rehovot, Israel.

Pharmacentra LLC provides marketing and communications programs for the pharmaceutical and insurance industries. The private company is based in Norcross, GA. The CEO of the company is Dan Berman.

EndoSpan Ltd. develops novel endovascular system for endovascular aortic aneurysm repair. The firm is opening up options for repairing aneurysms and dissections in patients with anatomy previously unsuitable for endovascular therapy. The company was founded by Rafi Benary and Alon Shalev in 2009 and is headquartered in Herzlia, Israel.

SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel.

PulmOne Advanced Medical Devices Ltd. develops devices designed to allow lung function testing. It manufactures and distributes the MiniBox, an office based solution providing complete lung function testing in a portable device. The company was founded by Avi Lazar in 2006 and is headquartered in Raanana, Israel.

Part of Medtronic Plc, Mazor Robotics LLC is a company that specializes in the Mazor X Stealth Edition robotic guidance platform. The company is based in Orlando, FL. The platform is equipped with advanced software, robotic technologies, navigation, and instrumentation to support predictable surgical procedures. Christopher Prentice has been the CEO of the company since 2014.

Owlytics Healthcare operates personalized physiology-tracking health detection platform. The company was founded by Gill Zaphrir and Yaron Recher in 2015 and is headquartered in Tel Aviv, Israel.

Qart Medical Ltd. is a medical, a clinical-stage medtech company, addressing the global infertility epidemic. The company was founded by Alon Shalev and Natan T. Shaked and is headquartered in Israel.

CardiacSense Ltd. is a digital health company based in Caesarea, Israel. The Israeli company has developed a medical watch that integrates proprietary patent-protected sensors and software algorithms to provide continuous measurement of parameters such as core temperature, respiratory rate, blood pressure, oxygen saturation, and heart rate at CE and FDA-mandated accuracies. This provides an alternative to costly and complex invasive devices, addressing the increasing demand for remote patient monitoring and tele-health. The private company was founded in 2009 by Eldad Shemesh and Liat Shemesh, with Eldad Shemesh serving as the CEO since incorporation.